INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 137 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2019. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,636 | -17.7% | 89 | 0.0% | 0.00% | -33.3% |
| Q2 2023 | $5,635 | +16.9% | 89 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $4,819 | +2.3% | 89 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $4,710 | -32.7% | 89 | -39.9% | 0.00% | -25.0% |
| Q3 2022 | $7,000 | -12.5% | 148 | 0.0% | 0.00% | -20.0% |
| Q2 2022 | $8,000 | 0.0% | 148 | 0.0% | 0.01% | +25.0% |
| Q4 2021 | $8,000 | +33.3% | 148 | 0.0% | 0.00% | +33.3% |
| Q3 2021 | $6,000 | 0.0% | 148 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $6,000 | +20.0% | 148 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $5,000 | -16.7% | 148 | -24.1% | 0.00% | -25.0% |
| Q4 2020 | $6,000 | +20.0% | 195 | 0.0% | 0.00% | -20.0% |
| Q2 2020 | $5,000 | +66.7% | 195 | -43.5% | 0.01% | +150.0% |
| Q3 2019 | $3,000 | -40.0% | 345 | -9.2% | 0.00% | -33.3% |
| Q2 2019 | $5,000 | 0.0% | 380 | 0.0% | 0.00% | -25.0% |
| Q1 2019 | $5,000 | -44.4% | 380 | -3.8% | 0.00% | 0.0% |
| Q3 2018 | $9,000 | – | 395 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |